Twelve New Zealand White rabbits (3.5–3.5 kg body weight) were used. All animals were treated according to the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research. Before lens fitting, all rabbits underwent a partial nictitating membranectomy while under anesthesia, to facilitate lens retention, as previously described,
31 and were allowed to recover for 1 week before the lens-wearing test was initiated. To establish an in vivo model of infection, we fitted one eye of each rabbit by using fluorescein with a polymethylmethacrylate (PMMA) lens (diameter, 14.0 mm; base curves, 7.60–8.20 mm). After 24 hours of lens wear, the lens was removed, 50 μL of a 1 × 10
9 CFU PA/mL suspension was applied to the posterior concave surface, and the lens was reinserted for an additional 24 hours of wear (
n = 5). Bacterial adherence to the lens surface was verified by laser scanning confocal microscopy. To test whether targeting DNA and F-actin polymers during lens wear would reduce the infection load, we fitted both eyes with PMMA lenses, as just described, for 24 hours (
n = 7), the lenses were removed, and PA was added as described. In one eye, the test compound was instilled into the post lens tear film four times over a 24-hour period, by gently lifting the lens edge under light anesthesia with an intramuscular injection of 50 mg/mL ketamine (Fort Dodge Animal Health, Fort Dodge, IA) and 5 mg/kg xylazine (AnaSed; Lloyd Inc. Veterinary Products, Shenandoah, IA). The test compound, 33 μg/mL DNase and 40 μM
d-Asp
30, was instilled with a preservative-free artificial tear as the vehicle (Refresh Tears; Allergan, Irvine, CA). The preservative-free artificial tear was instilled into the contralateral eye as the control. After lens wear, the animals were euthanatized by intravenous injection of 120 mg/kg pentobarbital sodium (Sleepaway; Fort Dodge Animal Health), and whole globes were enucleated for subsequent analysis.